Research Library — Page 16 | Reta Compare
402 research articles. Page 16 of 17.
Articles
- Retatrutide Shows Promising Weight Loss Results in Phase 2 Clinical Trial
- Retatrutide's Potential Role in Resolving Non-Alcoholic Fatty Liver Disease
- Retatrutide Shows Promising Results in Weight Loss and Cardiometabolic Health
- Significant Weight Loss Observed in Retatrutide Obesity Drug Study
- Retatrutide Shows Promising Weight Loss Results in Experimental Trials
- Retatrutide Shows Promising Weight Loss Potential Compared to Ozempic
- Retatrutide Shows Potential for Significant Weight Loss in Phase 2 Trial
- Mid-Stage Study Highlights Efficacy of Retatrutide for Weight Loss
- Retatrutide Shows Significant Weight Reduction in Obesity and Type 2 Diabetes
- Retatrutide Shows Promising Weight Reduction in Phase 2 Clinical Trial
- Retatrutide Shows Promising Weight Loss Results in Phase 2 Study
- Retatrutide Demonstrates Superior Weight Loss Compared to Established GLP-1 Agonists
- Retatrutide: Insights from a Phase 1b Trial of a Novel Triple Receptor Agonist
- Exploring Quad-Agonist GLP Drugs: The Next Generation After Retatrutide
- From Tirzepatide to Retatrutide and Beyond: A Pipeline Timeline
- GLP-1 + GIP + Glucagon Triple Agonists: Retatrutide as the Benchmark for Future Multi-Agonist Therapies
- Eli Lilly's Post-Retatrutide Pipeline: Future Directions Beyond LY3437943
- Comparing Quad-Agonists and Retatrutide in the Obesity and Metabolic Drug Pipeline
- Mechanistic Comparison of GLP-1/GIP/GCG/Amylin Quad vs. Retatrutide
- Comparing Hepatic and Metabolic Effects of Quadruple Agonists with Retatrutide
- Penta-Agonists Versus Retatrutide: A Theoretical Efficacy Comparison
- Lean Mass Preservation: Comparing Quad-Agonists to Retatrutide
- Cardiovascular Outcomes: Quad-Agonists Compared to Retatrutide
- Glycemic Control: Quad-Agonists and Retatrutide for Type 2 Diabetes
- Tolerability: Will Quad-Agonists Address GI Side Effects Seen with Retatrutide?